EYPT News and Press, EyePoint Pharmaceuticals Inc. From 05/04/22

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 – ...

- Betta Pharmaceuticals to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan; EyePoint retains all global ophthalmic rights for EYP-1901 elsewhere - - Partnership strengthens 2020 license agreement between EyePoint and Betta affiliate, Equinox Sciences, fo...

EyePoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.59 (-18.0% Y/Y) and the consensus Revenue Estimate is $9.89M (+35.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward ...

WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call a...

WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executi...

Shares of EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) traded at a new 52-week high today of $24.75. So far today approximately 56.2 million shares have been exchanged, as compared to an average 30-day volume of 197,000 shares. EyePoint Pharmaceuticals Inc is a pharmaceutical company. It ...

WATERTOWN, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted no...

EyePoint Pharmaceuticals (NASDAQ:EYPT) entered into a loan agreement providing for senior secured credit facilities in the amount of $45M with Silicon Valley Bank to replace its existing credit facility with CRG Servicing. Under agreement terms, a $30M term loan facility and an asset-bas...

WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has entered into a ...

Blue Sky potential due to potential blockbuster candidates with a differentiated mechanism of action. Ocular is working to leverage its proprietary technology platform to optimize drug delivery for additional eye diseases. In the second half of the year, the important data release...